Vascular-invasion-mediated interactions between activated articular chondrocytes and subchondral bone are essential for osteoarthritis (OA) development. Here, we determined the role of nutrient sensing mechanistic target of rapamycin complex 1 (mTORC1) signaling in the crosstalk across the bone cartilage interface and its regulatory mechanisms. Then mice with chondrocytespecific mTORC1 activation (Tsc1 CKO and Tsc1 CKO ER ) or inhibition (Raptor CKO ER ) and their littermate controls were subjected to OA induced by destabilization of the medial meniscus (DMM) or not. DMM or Tsc1 CKO mice were treated with bevacizumab, a vascular endothelial growth factor (VEGF)-A antibody that blocks angiogenesis. Articular cartilage degeneration was evaluated using the Osteoarthritis Research Society International score. Immunostaining and Western blotting were conducted to detect H-type vessels and protein levels in mice. Primary chondrocytes from mutant mice and ADTC5 cells were treated with interleukin-1b to investigate the role of chondrocyte mTORC1 in VEGF-A secretion and in vitro vascular formation. Clearly, H-type vessels were increased in subchondral bone in DMM-induced OA and aged mice. Cartilage mTORC1 activation stimulated VEGF-A production in articular chondrocyte and H-type vessel formation in subchondral bone. Chondrocyte mTORC1 promoted OA partially through formation of VEGF-A-stimulated subchondral H-type vessels. In particular, vascular-derived nutrients activated chondrocyte mTORC1, and stimulated chondrocyte activation and production of VEGF, resulting in further angiogenesis in subchondral bone. Thus a positivefeedback regulation of H-type vessel formation in subchondral bone by articular chondrocyte nutrient-sensing mTORC1 signaling is essential for the pathogenesis and progression of OA.
Introduction
O steoarthritis (OA) is a chronic, incurable, and destructive joint disease and a major cause of pain and disability in the aging population.
(1-3) Age, gender, and genetic predisposition are major intrinsic risk factors for OA. The OA disease process affects all joint tissues, and is characterized by progressive degeneration of articular cartilage, vascular invasion of the articular surface, subchondral bone remodeling, osteophyte formation, and synovial inflammation. (1, 4) There is no effective medical therapy for OA because of limited understanding of its pathogenesis. (5, 6) Chondrocytes are the only cells found in healthy cartilage, and their primary function is to maintain cartilage homeostasis. (7) During OA development, chondrocytes show aberrant proliferation, hypertrophy, activation, and senescence, accompanied by extracellular matrix degeneration in articular cartilage. (7) (8) (9) Although OA was initially thought to be driven only by cartilage degradation, (10, 11) pathological processes in subchondral bone and synovium are now also considered to be critical for its development. During OA, subchondral bone undergoes sclerosis, angiogenesis, microfracture, and the formation of cysts and osteophytes. Some of these changes are thought to occur in the early stages of OA. (12, 13) Progressive cartilage degradation and subchondral bone sclerosis are widely observed in OA. Synovial inflammation is detected in very early OA, while vessel formation is overexpressed in early OA.
(1) Furthermore, it has been reported that synovitis and subchondral bone cysts are respectively present in up to 50% and 57% of OA patients. (14, 15) However, the mechanisms underlying the activation of normally quiescent articular chondrocytes and the changes in subchondral bone are not fully understood.
Emerging evidence demonstrates that interactions between articular chondrocytes and subchondral bone are essential for the pathological changes during OA development. (16, 17) The close physical association and the presence of connections (microfractures, fissures, vascular channels, and blood vessels) between subchondral bone and articular cartilage suggests the biochemical and molecular crosstalk across the interface between healthy and osteoarthritic joints. (18, 19) Vascular invasion into articular surface is a hallmark of advanced OA. (20) The formation of new blood vessels not only supplies oxygen and nutrients but also mediates the molecular crosstalk across the bone cartilage interface. (21) (22) (23) Emerging evidence demonstrates that perfusion abnormalities in subchondral bone are associated with OA and avascular necrosis. (24) It has been shown that OA hypertrophic chondrocytes potentially express a phenotype promoting angiogenesis and the development of the hypertrophic chondrocyte phenotype in vitro requires the presence of serum (nutrients), (25, 26) suggesting that chondrocyte hypertrophy and cartilage angiogenesis are interdependent. (27, 28) However, the exact mechanism by which articular chondrocytes sense nutrients and biochemical factors and promote angiogenesis during OA progression is unknown.
Mechanistic target of rapamycin complex (mTORC)1 is a master regulator of cellular growth, proliferation, and metabolism in response to nutrients, growth factors, and stresses. (29) mTORC1 activation may play a vital role in chondrocyte metabolism and OA pathophysiology. (30, 31) Both cartilage-specific deletion of mTOR and pharmacological inhibition of mTORC1 decrease the severity of experimental OA in mouse models. (32) (33) (34) We recently showed that mTORC1 coordinates chondrocyte proliferation and differentiation during endochondral bone development, and mTORC1 activation stimulates articular chondrocyte aberrant proliferation and differentiation to initiate OA in mice. (35, 36) However, how chondrocyte mTORC1 is activated during OA development and whether chondrocyte mTORC1 contributes to osteoarthritic angiogenesis are unknown.
In this study, we demonstrated that vascular-derived nutrients activated chondrocyte mTORC1, and stimulated chondrocyte proliferation and hypertrophic differentiation, and production of vascular endothelial growth factor (VEGF), resulting in further angiogenesis. Thus, we established a novel crosstalk between articular chondrocytes and osteoarthritic subchondral blood vessels via a nutrient-sensing, signaling-mediated, positive feedback mechanism.
Materials and Methods

Animals
All animal experiments were approved by the Southern Medical University Animal Care and Use Committee. The Col2a1-cre mouse line was a generous gift from Dr. Xiao Yang (Academy of Military Medical Sciences, Beijing, China). Tsc1 fl/fl mice, Raptor fl/fl mice, and inducible Col2a1-Cre/ERT mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA; Jax no. 005680, Jax no. 013188, and no. 006774, respectively). Other conditional KO mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA): floxed Tsc1 mice (Jax#005680), and floxed Raptor mice (Jax#013188), inducible Col2a1-Cre/ERT transgenic mice (Jax#006774). Six-week-old male C57BL/6 mice were purchased from the Laboratory Animal Centre of Southern Medical University. To generate chondrocyte-specific Tsc1 deletion mice (Tsc1 fl/fl ; Col2a1-Cre), Tsc1 fl/fl mice were hybridized with Col2a1-cre mice, as reported. (35, 36) We generated inducible chondrocyte-specific Tsc1 deletion mice in the same way. Mice with Col2a1-specific deletion of Tsc1 were defined as Tsc1 CKO mice and mice with inducible Col2a1-specific deletion of Tsc1 were defined as Tsc1 CKO ER mice. Eight-week-old Tsc1 CKO ER mice were treated with tamoxifen (100 mg/g body weight) by intraperitoneal injection for 5 days, knocking out the Tsc1 gene in the chondrocytes. Genotyping was performed on genomic DNA from tail biopsies, and primers used were as follows: loxP Tsc1 loxP primer up, 5 0 -GTC ACG ACC GTA GGA GAA GC-3 0 , and down, 5 0 -GAA TCA ACC CCA CAG AGC AT-3 0 ; Col2a1-Cre forward, 5 0 -GCA TCG ACC GGT AAT GCA GGC-3 0 , and reverse, 5 0 -GAG GGT CCA GCC CGA GCT ACTT-3 0 ; Col2a1-Cre/ERT forward, 5 0 -CAC TGC GGG CTC TAC TTC AT-3 0 , and reverse, 5 0 -ACC AGC AGC ACT TTT GGA AG-3 0 (both from Sangon Biotech, China).
Mice model
Eight-week-old control mice and Tsc1 CKO mice were subjected to DMM to induce OA. We quantified articular cartilage degeneration by the Osteoarthritis Research Society International (OARSI) scoring system. Collagenase-induced osteoarthritis (CIOA) or anterior cruciate ligament transection (ACLT) was induced in mice as described. (37, 38) Antigen-induced arthritis (AIA) was induced rheumatoid arthritis (RA) in mice, using methylated bovine serum albumin (mBSA). Briefly, mice were sensitized subcutaneously with an emulsion containing mBSA (500 mg) and Freund's complete adjuvant (2 mg/mL of inactivated Mycobacterium tuberculosis) (both from Sigma-Aldrich, St. Louis, MO, USA) diluted 1:1 in phosphate buffered saline (PBS). Booster injections of mBSA dissolved in Freund's incomplete adjuvant (without M. tuberculosis) were given 7 and 14 days after the first immunization. Sham-immunized mice received similar injections but without the antigen. (39) Cells and cartilage explants
The prechondrocyte cell line, ATDC5 (Tsukuba, Japan), was maintained in DMEM/F12 (Gibco, Grand Island, NY, USA) with 10% FBS (Gibco), 100 U/mL penicillin, and 100 mg/mL streptomycin sulfate (Life Technologies, Inc., Grand Island, NY, USA), at 37°C with 5% CO 2 . We dissected rib cartilage from newborn mice (24-72 hours) under a stereo light microscope to harvest primary chondrocytes. After trypsin digestion for 30 min, primary chondrocytes were separated and purified, and digested in 0.1% collagenase type II (Sigma) with 10% FBS, 100 U/mL penicillin, and 100 mg/mL streptomycin sulfate at 37°C for 4 to 6 hours. Primary chondrocytes were resuspended and seeded in a 24-well plate and cultured in DMEM/F12 with 10% FBS, 100 U/mL penicillin, and 100 mg/mL streptomycin sulfate at 37°C with 5% CO 2 . Femoral heads were isolated from 8-week-old mice. Explants cultured in DMEM/F12 were treated with 10mM PBS for 1 hour, followed by treatment with 50 ng/mL recombinant mouse or human interleukin (IL)-1b in PBS/0.1% BSA, or with PBS/0.1% BSA alone. The explants were harvested and the medium was collected after 3 days in culture.
Drug treatment
Cells were treated with IL-1b (50 ng/mL; PeproTech, Rocky Hill, NJ, USA) for 24 hours to mimic OA in vitro. Two-week-old Tsc1 CKO mice were treated with rapamycin (1 mg/kg/day; Sigma) by intraperitoneal injection for 4 weeks. Bevacizumab (25 mg/kg/ week; Roche, USA) was administered to 4-week-old Tsc1 CKO mice by intraarticular injection for 4 weeks before the mice were killed. Similarly, 8-week-old control mice and Tsc1 CKO mice after surgery were treated with or without bevacizumab for 5 weeks (Supporting Fig. 1 ).
In vitro tube formation assay
The 96-well plates were coated with 20 mL growth-factordepleted Matrigel (BD Biosciences, Australia). Matrigel solidified for 45 min at 37°C, and human umbilical vein endothelial cells (HUVECs) were seeded at a density of 50,000/well. One hundred microliters (100 mL) of conditional cell suspension was added and photomicrographs were obtained 9 hours later. Tube length was measured by Image-Pro Plus 6.0.
Elisa
Cell supernatant was analyzed by Mouse VEGF-A ELISA Kit (#EEL-M0050; Elabscience Biotechnolog, China).
Preparation of decalcified sections, histochemistry, immunostaining, and immunohistochemistry
Knee joints freshly dissected from mice were fixed for 24 hours in 4% paraformaldehyde at 4°C then decalcified for 30 days in 14% EDTA (pH 7.4) at 25°C. Tissues were embedded in paraffina n d sectioning continuously (3 mm thick). Safranin-O/Fast Green staining was performed as described. (35) Terminal deoxynucleotidyl transferase (TdT) dUTP nick-end labeling (TUNEL) assay was performed with the In Situ Cell Death Detection Kit TMR Red (Roche). For immunofluorescence and immunohistochemistry, sections were treated with 0.1 mg/mL proteinase K (Sigma) for 10 min at 37°C or soaked in citrate buffer (10mM citric acid, pH 6.0) for 16 to 18 hours at 60°C to unmask antigen after deparaffinization and rehydration. For immunohistochemistry we added 3% hydrogen peroxide for 10 min. Sections were blocked with 1% sheep serum at 37°C for 1 hour and incubated with primary antibodies (in 1% BSA, 0.1% Triton X-100) at 4°C overnight. Sections were incubated with secondary antibodies at 37°C for 1 hour. Species-matched antibodies labeled with Alexa Fluor 488 and Alexa Fluor 594 or horseradish peroxidase were used (1:100 in 1% BSA) as described. (40) Nuclei were labeled with 4 0 ,6-diamidino-2-phenylindole (Thermo Fisher, USA) before imaging. For immunohistochemistry, we used 3,3 0 -diaminobenzidine to observe chromogen and hematoxylin to counterstain. In situ hybridization with digoxin-labeled probes was performed using a CXCL9 mRNA (#MK3237; Boster, China).
Western blotting
Lysis buffer was prepared with 10% glycerol, 2% sodium dodecyl sulfate (SDS), 10mM dithiothreitol, 10mM Tris-HCl (pH 6.8), 1mM phenylmethylsulfonyl fluoride, and 10% b-mercaptoethanol.
Tissues and cells were lysed by lysis buffer at 98°C for 10 min. Samples were separated by SDS-PAGE for 90 min. Samples were blotted onto nitrocellulose membranes for 1 hour and incubated with primary antibodies (in 5% BSA, 0.2% NaN 3 )a t 4°C overnight. Samples were incubated with secondary antibodies at 37°C for 1 hour.
Antibodies
The following antibodies were used: rabbit anti-p S6 (S235/236) ( 
Statistical analysis
Experiments were performed three times. All data are presented as mean AE SD using SPSS version 19.0 software (IBM Corp., Armonk, NY, USA) and curve analysis was determined using GraphPad Prism 5.0 (GraphPad Software, Inc., La Jolla, CA, USA). The data among different groups were analyzed using multiple factorial analysis of variance. The data in each group were analyzed using unpaired, two-tailed Student's t test. The level of significance was set at p < 0.05.
Results
H-type vessels are increased in subchondral bone in DMM and aged mice H-type vessels are a specific subtype defined by high co-staining for CD31 and endomucin (CD31 hi Emcn hi ), which has been identified to couple angiogenesis and osteogenesis. (41, 42) To determine whether H-type vessels in subchondral bone changed during OA progression, we performed double immunofluorescence staining for CD31 and endomucin in a DMM model. CD31
hi Emcn hi blood vessels were significantly increased in the subchondral bone of DMM mice (Fig. 1A-D) . We observed more H-type vessels in the injured meniscus, but fewer vessels in the intact meniscus in the DMM model (Supporting Fig. 2) . Age is the most prominent risk factor for the development of OA. A previous study has shown H-type vessels are drastically reduced in the long bones of aged mice, contributing to decreased osteogenesis and osteoporosis. (41) We also observed pronounced reduction of H-type vessels in the metaphyses in aged mice (Fig. 1E-H) . Surprisingly, H-type vessels were markedly increased in subchondral bone of aged mice (Fig. 1E-H) , suggesting that distinct microenvironments or mechanisms may control H-type vessel formation in subchondral bone. All these results indicate that H-type vessel formation in subchondral bone is strongly correlated with OA development.
Articular chondrocyte mTORC1 activation stimulates angiogenesis in subchondral bone OA hypertrophic chondrocytes may stimulate vascular formation via releasing angiogenic factors such as VEGF. (43) We previously generated mice with chondrocyte-specific deletion of tuberous sclerosis (TSC)1, an upstream inhibitor of mTORC1 (Tsc1
Col2-Cre mice were referred to as Tsc1 CKO; Tsc1 fl/fl mice were referred to as control). We found that articular chondrocyte mTORC1 activation stimulated aberrant proliferation of chondrocytes, and hypertrophic differentiation to initiate OA. (35, 36) We also examined mTORC1 signaling in articular chondrocyte in CIOA and ACLT OA models and in AIA rheumatoid arthritis mouse model. Thus, mTORC1 activation may be a general mechanism of joint tissue response damage in mice (Supporting Fig. 3) .
We examined whether chondrocyte mTORC1 regulated vascular formation in subchondral bone. mTORC1 was hyperactivated in articular chondrocytes of Tsc1 CKO mice, as manifested by high levels of p-S6(S235/236) in these cells ( Fig. 2A, B) . Subchondral bone of the mutant mice was highly vascularized, and CD31 þ and CD31 hi Emcn hi blood vessels were markedly increased in subchondral bone of 8-week-old Tsc1 CKO mice (Fig. 2C-F) . These mice also developed severe OA (Fig. 2G,  H) . Importantly, rapamycin treatment inhibited mTORC1 and reversed the angiogenesis and OA phenotype of Tsc1 CKO mice ( Fig. 2A-H) . Furthermore, chondrocyte mTORC1 activation also promoted H-type vessel formation in the synovium of Tsc1 CKO mice (Supporting Fig. 4) .
To duplicate the process of angiogenesis during OA development, we generated Tsc1 CKO ER mice and Raptor (a specific component of mTORC1) CKO ER mice and specifically activated or disrupted chondrocyte mTORC1 at adult stages. Eight-week-old mice were injected with tamoxifen or PBS for 5 days and subjected to DMM surgery (Tsc1 fl/fl Cre/ERT and Raptor fl/fl Cre/ERT were injected with PBS and referred to as control, respectively). Five weeks postsurgery, the targeting efficiency and specificity were confirmed by mTORC1 activation or inhibition in articular chondrocytes of Tsc1 CKO ER and Raptor CKO ER mice (Fig. 2I, L) . Importantly, H-type vessels were significantly increased in the subchondral bone of Tsc1 CKO ER , but decreased in that of Raptor CKO ER mice (Fig. 2J, M) . Consistently, OA progression was markedly accelerated or delayed by constitutive activation or inhibition of mTORC1 in chondrocytes (Fig. 2K, N) . These findings suggest that articular chondrocyte mTORC1 promotes subchondral angiogenesis and H-type vessel formation during OA progression. mTORC1 activation promotes articular chondrocyte VEGF-A production during OA development VEGF-A is an established important proangiogenic factor expressed by hypertrophic chondrocytes in OA. (44) To explore the mechanism by which chondrocyte mTORC1 stimulates subchondral angiogenesis, the potential role of VEGF-A in this process was investigated. As expected, increased VEGF-A-positive cells were detected in OA chondrocytes (Fig. 3A,  B) . Upon IL-1b stimulation, secretion of VEGF-A was enhanced in primary cultured chondrocytes (Fig. 3C) . The supernatant of OA chondrocyte culture promoted HUVEC in vitro tube formation (Fig. 3D, E) . Moreover, other potential triggers, such as transforming growth factor (TGF)-b,w e r e investigated. We also observed that TGF-b enhanced VEGF-A s e c r e t i o ni nc u l t u r e da r t i c u l a rcartilage explants. However, t h ee f f e c to fT G F -b1o nV E G F -Ae x p r e s s i o nw a sn o t rapamycin dependent. The mechanisms through which TGF-b1 regulates VEGF-A need to be further investigated (Supporting Fig. 5 ). Strong VEGF-A immunostaining and marked increase of VEGF-A-positive articular chondrocytes were observed in Tsc1 CKO mice but not in their littermate controls or rapamycin-treated Tsc1 CKO mice (Fig. 3F, H) . Cultured chondrocytes from Tsc1 C K Om i c es e c r e t e dm o r e VEGF-A than the control and rapamycin-treated Tsc1 CKO mice did (Fig. 3I) . Accordingly, in vitro tube formation stimulated by the supernatant of Tsc1 CKO chondrocyte culture was significantly enhanced as compared with that of control and rapamycin-treated mice (Fig. 3G, J) . Consistent with the increased H-type vessels in subchondral bone of aged mice (Fig. 1E-H) , mTORC1 activity (p-S6) and VEGF-A expression in articular chondrocytes were enhanced in aged mice (Supporting Fig. 6) . A similar result can be observed in cartilage explant (Supporting Fig. 5 ). All these results suggest that mTORC1 activation induces production of VEGF-A in OA articular chondrocytes.
Chondrocyte mTORC1 activation promotes OA partially through VEGF-A-stimulated subchondral H-type vessel formation
We next investigated the role of VEGF-A in chondrocyte mTORC1-stimulated subchondral angiogenesis and OA development. Four-week-old Tsc1 CKO mice were intraarticularly injected with bevacizumab; a recombinant monoclonal anti-VEGF-A antibody that blocks angiogenesis. (44) Four-week treatment with bevacizumab not only markedly reduced subchondral H-type vessel formation ( Fig. 4A, C; Supporting  Fig. 4 ), but also prevented cartilage proteoglycan loss and cartilage degeneration and reduced OARSI score in Tsc1 CKO mice (Fig. 4B, D) . Similarly, VEGF-A antibody significantly decreased subchondral H-type vessels and delayed OA development in Tsc1 CKO ER mice (Fig. 4E-H) . These findings clearly demonstrate that VEGF-A-stimulated subchondral Htype vessel formation is essential for chondrocyte mTORC1 activation-induced OA.
Enhanced H-type vessel formation in subchondral bone contributes to chondrocyte mTORC1 activation and OA development Although it is well established that chondrocyte mTORC1 activation plays a vital role in the pathogenesis of OA, little is known about the mechanism through which articular chondrocyte mTROC1 is activated during this process. Bevacizumab not only blocked subchondral H-type vessel formation (Fig. 5A, B) , but also reduced chondrocyte mTORC1 activation in DMM OA mice (Fig. 5C-E) . Serum or nutrients (amino acids) stimulated mTORC1 in culture chondrocyte cell line ATDC5 that were subjected to serum or nutrient starvation (Fig. 5F, G) . Similarly, serum or amino acids strongly activated mTORC1 in primary cultured chondrocytes and cartilage explants (Fig. 5H-K) . We further examined the effect of cyclic stretch on the capability of chondrocytes to promote vessel formation. We found that stretch significantly enhanced mTORC1 activity and the ability of chondrocytes to promote tube formation (Supporting Fig. 7) . These findings imply that chondrocyte mTORC1 activation enhances nutrients and factors supplementation by increasing angiogenesis during OA development in mice.
Previous studies have shown that mTORC1 activation induces articular chondrocyte hypertrophic differentiation, (35) autophagy deficiency and apoptosis to initiate and promote OA. (34) Blockade of angiogenesis by bevacizumab reduced chondrocyte mTORC1 activity in OA mice ( Fig. 5C-E) ; therefore, we examined the effect of bevacizumab on these chondrocyte phenotypes related to mTORC1 in OA. As expected, chondrocyte hypertrophic differentiation was prevented by blockade of angiogenesis, manifested by reduced matrix metallopeptidase (MMP)13, collagen X, and runt-related transcription factor (Runx)2 expression in bevacizumab-treated OA mice (Fig. 6A-F) . Furthermore, autophagy marker light chain 3 (LC3B)-positive chondrocytes were augmented while TUNEL-positive cells were reduced by bevacizumab (Fig. 6G-J) , indicating that OA chondrocyte autophagy was recovered and cell death was decreased. These results showed that enhanced angiogenesis may activate chondrocyte mTORC1 and promote OA in mice.
Discussion
Accumulating evidence demonstrates that OA is a systemic disease, not just of cartilage or bone. Pathological changes in cartilage and subchondral bone and crosstalk between cartilage and subchondral play a vital role in this process. (45) Angiogenesis and biochemical interplay between subchondral bone and articular cartilage are critical in the pathogenesis of OA. Here, we demonstrate that during OA development, activation of mTORC1 in articular chondrocytes is essential for subchondral H-type vessel formation via production of VEGF. Moreover, subchondral angiogenesis activates nutrient-sensing mTORC1 signaling in articular chondrocytes. These data establish a novel positive-feedback regulation of subchondral vascular formation by articular chondrocyte nutrient-sensing signaling, which is essential for the pathogenesis of OA (Supporting Fig. 8 ).
H-type vessels are a specific subtype that couples angiogenesis with osteogenesis. (41, 42) A recent study has shown that H-type vessels are increased in subchondral bone (osteoid islet) of mouse models of anterior cruciate ligament transection. (46) However, how H-type vessel formation is induced during OA is unknown. We found that H-type vessels were increased in the subchondral bone of DMM mice. Importantly, activation of chondrocyte mTORC1 is sufficient to stimulate H-type vessel formation and OA, while inhibition of chondrocyte mTORC1 prevents subchondral H-type vessel formation and attenuates OA development. These findings suggest that articular chondrocyte mTORC1 is essential for H-type vessel formation, which may couple subchondral angiogenesis with osteogenesis and contribute to the sclerosis and the formation of cysts and osteophytes in OA. However, the implications of increased vessel formation may be much more complex and not necessarily serum derived. Biomechanics may also contribute to vessel formation. We observed that stretch significantly enhanced mTORC1 activity and the ability of chondrocyte to promote tube formation. Targeting mTORC1 may attenuate OA progression partially by prevention of pathological angiogenesis and osteophytes formation. It has been shown that H-type vessels are markedly reduced in long bones of aging mice, accompanied by reduced osteoprogenitors, osteogenesis, and bone mass. (41, 47) We observed pronounced reduction of H-type vessels in metaphyseal bone marrow cavities, but increased vessels in subchondral bone of aged mice. We speculate that the inconsistency may have resulted from the distinct biochemical and biomechanical microenvironment between subchondral bone and long bone marrow cavities, because activated articular chondrocytes may release many cytokines and factors such as VEGF to subchondral bone during pathogenesis of OA. (25) Subchondral vessels may contribute to chondrocytes and osteoblasts, while metaphyseal vessels may contribute to osteoblasts. Bone vasculature is modulated by numerous biochemical factors through different signaling pathways. Halofuginone can reduce vessel formation through inhibiting MMP2 and collagen type a1expression. (48) Furthermore, other studies have shown that TGF-b signaling can regulate H-type vessels (46) and we also observed that TGF-b enhanced VEGF-A secretion in cultured articular cartilage explants. However, the mechanisms through which TGF-b1 regulates VEGF-A need to be further investigated. Similarly, we have recently shown that activation of mTORC1 in osteoblast prevents H-type vessel formation in long bone, (40) while activation of mTORC1 in chondrocytes stimulated vessel formation in subchondral bone in the current study. We revealed that mTORC1 activation stimulates the production of VEGF and chemokine XCX ligand (CXCL)9 in osteoblasts. However, CXCL9 can interact with VEGF and prevent its binding to endothelial cells, thus abrogating angiogenesis in bone. Moreover, CXCL9 is constitutively expressed by osteoblasts residing in bone, (40) but was undetectable in chondrocytes (Supporting Fig. 9 ). Although blocking subchondral vascular formation by anti-VEGF-A antibody bevacizumab ameliorates OA in mice according to previous reports (44) and the results from this study, systemic targeting of H-type vessels for OA prevention and treatment should be undertaken cautiously because of the increased risk for osteoporosis.
Emerging evidence highlights the vital role of mTORC1 in the pathogenesis and progression of OA. (30) (31) (32) (33) (34) (35) (36) mTORC1 is activated in articular chondrocytes in experimental OA, agerelated OA, and RA mice. Both cartilage-specific deletion of mTOR (33) and pharmacological inhibition of mTORC1 by rapamycin have been shown to decrease the severity of experimental OA in mouse models. (32, 34) We have found that endogenously produced n-3 polyunsaturated fatty acids (PUFAs) inhibit mTORC1 signaling and attenuate OA p r o g r e s s i o ni nm i c e . (49) Mice with chondrocyte-specific activation of mTORC1 develop a severe OA phenotype. (35) However, the mechanism underlying mTORC1 activation in OA chondrocytes is not known. mTORC1 is the major intracellular nutrient sensing signaling that is activated by n u t r i e n t ss u c ha sa m i n oa c i d sa n dg l u c o s et oc o n t r o lc e l l growth and metabolism. (29, 50) We found that blocking subchondral angiogenesis reduced mTORC1 activation in OA articular chondrocytes. We suppose that normal cartilage is avascular with low levels of nutrients, and the articular chondrocytes are maintained in a quiescent state with low mTORC1 activity. During development of OA, cartilage is vascularized and more nutrients are carried to activate chondrocyte mTORC1. This suggests that subchondral vascular formation is important for sustained cartilage chondrocyte mTORC1 activation during OA development.
Clinically, characteristics of OA include osteophyte formation, subchondral bone sclerosis, disruption of tidemark accompanied by angiogenesis at the osteochondral junction, synovitis, and degeneration and loss of articular cartilage. (1, 3) Subchondral bone cysts do not necessarily lead to OA, but they can suggest abnormal interaction in subchondral bone. (51) Early osteophyte formation may provide a mechanism for repairing damage during mechanical loading. (52) Some osteophytes without joint space narrowing can be a sign of compensation and restoration of homeostasis. Therapy that is able to target the multiple pathological changes in joints is desirable. Evidence from this study supports that the mTORC1 pathway is one of the critical signaling pathways that activate cellular and molecular processes in crosstalk among joint compartments. Previous studies have established that activation of mTORC1 inhibits autophagy to promote articular chondrocyte apoptosis during OA development. (32, 34) We have shown that mTORC1 activation induces chondrocyte aberrant proliferation, differentiation, and activation to initiate cartilage degeneration and OA development. (35) The current study shows that mTORC1 activation stimulates angiogenesis in subchondral bone and synovial membrane and establishes links between cartilage, subchondral bone, and synovial membranes via an mTORC1-mediated positive feedback mechanism. In this model it is hard to explain whether cartilage or bone is a trigger, but it may show that multiple OA pathological joint compartments benefitf r o mt a r g e t i n go f mTORC1.
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